相关实验视频

Updated: May 31, 2025

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

新辅助化疗作为高级上皮卵巢癌的预康复计划的有效性

Valentina Ghirardi¹, Claudia Marchetti², Diana Giannarelli³

¹Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

|January 24, 2025

概括

新辅助化疗 (NACT) 改善了高风险 (HR) 晚期卵巢癌 (AOC) 患者的术前条件,减少了严重的术后并发症而不会影响存活率. 这支持在选定的HR患者中将NACT与预康复结合起来.

科学领域:

妇科瘤学妇科瘤学
手术瘤学手术瘤学
医学瘤学医学瘤学

背景情况:

晚期卵巢癌 (AOC) 通常呈现出不良的临床条件,不适合立即手术.
大约70%的AOC患者在诊断时患有晚期疾病.
识别和管理高风险 (HR) 患者的术后并发症至关重要.

研究的目的:

评估新辅助化疗 (NACT) 是否可以改善HR AOC患者的手术前特征.
为了比较HR AOC患者的发病率和生存结果,这些患者接受了NACT之后的间隔手术与初级手术 (PCS) 相比.

主要方法:

从2013-2022年对FIGOIII期+AOC患者的回顾性分析.
高风险 (HR) 标准包括低专蛋白,晚年,表现不佳状态或预期的复杂手术.
在NACT间隔的细胞削减手术 (HR-NACT) 和初级手术 (PCS) 组之间的比较.

主要成果:

NACT改善了临床变量,包括ECOG性能状态和专蛋白水平,特别是在3-4个周期后.
与HR-PCS患者相比,HR-NACT患者的严重术后并发症率明显较低.
在手术后并发症,无病生存期 (DFS) 或整体生存期 (OS) 中没有发现显著差异.

结论:

短期NACT可以优化选择HR AOC患者的手术前条件.
将NACT与非干预性预康复相结合,提供了一种改善HR患者治疗结果的策略.
在高风险的晚期卵巢癌患者中,NACT可能会降低外科病率.

关键词:

疾病发病率疾病发病率新辅助化学疗法新辅助化学疗法卵巢癌是发生在卵巢中的癌症.在康复前,进行了预康复.

更多相关视频

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...